Biocon Limited has announced several significant decisions following its Board Meeting held on December 6, 2025. These decisions include an increase in authorised share capital, a major acquisition involving Biocon Biologics Limited (BBL), a preferential equity issue worth ₹6,950 crore, and approval for additional fund raising of up to ₹4,500 crore.
1. Increase in Authorised Share Capital
The Board approved enhancing the company’s authorised share capital from ₹700 crore to ₹900 crore, increasing the number of equity shares from 140 crore to 180 crore (face value ₹5 each). This change will require shareholder and regulatory approvals and includes a revision to the company’s Memorandum of Association.
2. Acquisition of Biocon Biologics (BBL) Shares
Biocon will acquire equity shares of its material subsidiary, Biocon Biologics Limited, from four existing shareholders:
Mylan Inc.
Serum Institute Life Sciences Pvt. Ltd.
Tata Capital Growth Fund II
Activ Pine LLP
The acquisition is a strategic step to fully integrate BBL with Biocon, enabling a unified corporate structure, enhanced capital allocation, and operational synergies. This move aims to strengthen Biocon’s position in the global biosimilars market, leveraging BBL’s commercial footprint in 120+ countries and strong biologics pipeline.
The total acquisition involves:
40.56 crore BBL shares in aggregate
Part payment via share swap (₹6,950 crore)
Additional USD 400 million cash remittance to Mylan
3. Preferential Issue of Equity Shares (₹6,950 Crore)
To complete the share swap, Biocon will issue 17,12,79,553 new equity shares at a price of ₹405.78 per share to the above BBL shareholders.
This will be a non-cash consideration, executed as part of the acquisition.
4. Fund Raising of Up to ₹4,500 Crore
The Board has approved raising up to ₹4,500 crore through one or more instruments, including:
Qualified Institutions Placement (QIP)
Rights issue
Preferential allotment
Private placement of equity or debt securities
This fundraise will help Biocon meet cash obligations relating to the BBL transaction, especially payments to Mylan.
5. EGM Scheduled for December 31, 2025
To obtain shareholder approvals for these proposals, Biocon will convene an Extra-Ordinary General Meeting via video conferencing on December 31, 2025.
6. Commercial Papers Issue for Interim Funding
To manage immediate liquidity needs, the company will issue Commercial Papers worth up to ₹1,800 crore, primarily for interim settlement of payments to Mylan until the larger fundraise is completed.
